Statera rises on submission of late-stage trial protocol to FDA

Statera Biopharma

29/12/2021 14:25

** Drug developer Statera BioPharma's shares  STAB.O  up
2.3% at $2.21 premarket
    ** Says submitted late-stage clinical trial protocol for its
lead drug candidate STAT-201 to U.S. FDA for treatment of
pediatric Crohn's Disease  urn:newsml:reuters.com:*:nGNX60Ck2L
    ** Adds that trial sites currently being selected and
enrollment is expected to launch in early 2022
    ** Up to Tuesday's close, stock had fallen 37% YTD

 (Reporting by Leroy Leo)
 ((Leroy.Dsouza@thomsonreuters.com;))